1690O NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study

Eric Jonasch, Bradley A. McGregor, Pavlos Msaouel, T. Logan, Evan Hall, M.A. Bilen, Gerald S. Falchook, B. Shuch, Yousef Zakharia, R. J. Hauke, Michael S. Gordon, A-R. Naqash, Christopher W. Ryan, Ramaprasad Srinivasan, Jim Xiao, Weimin Sun, Maricris Esguerra, Lu Gang, Joanne Lager, T.K. Choueiri